Gilles Truc

Gilles Truc

Auto-generated profile, based on publicly available information

Gilles Truc

Georges François Leclerc Cancer Center, Dijon, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JBJihane Boustani
Jihane Boustani
BLBenoît Lecoester
Benoît Lecoester
JBJeremy Baude
Jeremy Baude
CLCharlène Latour
Charlène Latour
OAOlivier Adotevi
Olivier Adotevi
GTGilles Truc
Gilles Truc
Immune checkpoint inhibitors have been associated with long-term complete responses leading to improved overall survival in several cancer types. However, these novel immunotherapies are only effective in a small proportion of patients, and therapeutic resistance represents a major limitation in clinical practice. As with chemotherapy, there is substantial evidence that radiation therapy promotes anti-tumor immune responses that can enhance systemic responses to immune checkpoint inhibitors. In this review, we discuss the main preclinical and clinical evidence on strategies that can lead to an enhanced response to PD-1/PD-L1 blockade in combination with radiation therapy. We focused on central issues in optimizing radiation therapy, such as the optimal dose and fractionation for improving the therapeutic ratio, as well as the impact on immune and clinical responses of dose rate, target volume, lymph nodes irradiation, and type of radiation particle. We explored the addition of a third immunomodulatory agent to the combination such as other checkpoint inhibitors, chemotherapy, and treatment targeting the tumor microenvironment components. The strategies described in this review provide a lead for future clinical trials.

27 January 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
DTDavid Thibouw
David Thibouw
GTGilles Truc
Gilles Truc
ABAurélie Bertaut
Aurélie Bertaut
CCCédric Chevalier
Cédric Chevalier
LALéone Aubignac
Léone Aubignac
Céline MirjoletCéline Mirjolet
Céline Mirjolet

29 November 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
CDClaire Vautravers Dewas
Claire Vautravers Dewas
PMPhilippe Maingon
Philippe Maingon
CDCécile Dalban
Cécile Dalban
APAurélie Petitfils
Aurélie Petitfils
KPKarine Peignaux
Karine Peignaux
GCGilles Créhange
Gilles Créhange
Background: Chemoradiation is the standard treatment for anal cancer. 3D conformal radiotherapy (3D-CRT) is usually split in 2 sequences with a therapeutic break (gap) in between. Intensity-modulated radiation therapy (IMRT) makes it possible to reduce treatment time by abandoning this gap. The purpose of this study was to compare outcomes and toxicities in patients treated with either IMRT or 3D-CRT. Methods: Between 2004 and 2011, the data of 51 patients treated with exclusive radiotherapy with or without concomitant chemotherapy for non-metastatic anal carcinoma were retrospectively analyzed. Twenty-seven patients were treated with 3D-CRT and 24 patients with IMRT, with a median dose delivered to the tumor of 59.4Gy [30.6-66.6], whatever the radiotherapy technique (p= 0.99). The median follow-up was 40 months [26.4-51.6]. Results: There was no difference between the two groups for response to treatment (p= 0.46). Two-year overall survival, locoregional relapse-free survival and colostomy-free survival rates were 88.5%, 63% and 60.3%, respectively for the IMRT group and 81%, 76.5% and 81.1% for the 3D-CRT group (all NS). Ten patients (37%) in 3D-CRT and 11 patients (45.8%) in IMRT (p= 0.524) had grade 3 acute toxicity. No grade 4 toxicity occurred. Conclusions: Our study suggests that further investigations concerning the use of IMRT to treat cancer of the anus are warranted. IMRT makes it possible to remove the gap, but with no impact on the prognosis. Nonetheless, a longer follow-up is essential to determine whether or not IMRT has an impact on late toxicity, local control and survival compared with conventional 3D-CRT.

1 October 2013 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
GTG. Truc
G. Truc
ÉMÉ. Martin
É. Martin
Céline MirjoletCéline Mirjolet
Céline Mirjolet
JCJ. Chamois
J. Chamois
APA. Petitfils
A. Petitfils
GCG. Créhange
G. Créhange

1 May 2016 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
GTG. Truc
G. Truc
VBV. Bernier
V. Bernier
Céline MirjoletCéline Mirjolet
Céline Mirjolet
CDC. Dalban
C. Dalban
FMF. Mazoyer
F. Mazoyer
GNGeorges Noel
Georges Noel

17 September 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
CACaroline Azelie
Caroline Azelie
MGMélanie Gauthier
Mélanie Gauthier
Céline MirjoletCéline Mirjolet
Céline Mirjolet
LCLuc Cormier
Luc Cormier
EMEtienne Martin
Etienne Martin
GCGilles Créhange
Gilles Créhange
Background: To investigate whether patients treated for a localized prostate cancer (PCa) require a radical prostatectomy followed by postoperative radiotherapy or exclusive radiotherapy, in the modern era of image guided IMRT. Methods: 178 patients with PCa were referred for daily exclusive image guided IMRT (IG-IMRT) using an on-line 3D ultra-sound based system and 69 patients were referred for postoperative IMRT without image guidance after radical prostatectomy (RP + IMRT). Patients were matched in a 1:1 ratio according to their baseline risk group before any treatment. Late toxicity was scored using the CTV v3.0 scale. Biochemical failure was defined as a postoperative PSA ≤ 0.1 ng/mL followed by 1 consecutive rising PSA for the postoperative group of patients and by the Phoenix definition (nadir + 2 ng/mL) for the group of patients treated with exclusive radiotherapy. Results: A total of 98 patients were matched (49:49). From the start of any treatment, the median follow-up was 56.6 months (CI 95% = [49.6-61.2], range [18.2-115.1]). No patient had late gastrointestinal grade ≥ 2 toxicity in the IG-IMRT group vs. 4% in the RP + IMRT group. Forty two percent of the patients in both groups had late grade ≥ 2 genitourinary toxicity. The 5-year FFF rates in the IG-IMRT group and in the RP + IMRT groups were 93.1% [80.0-97.8] and 76.5% [58.3-87.5], respectively (p = 0.031). Conclusions: Patients with a localized PCa treated with IG-IMRT had better oncological outcome than patients treated with RP + IMRT. Further improvements in postoperative IMRT using image guidance and dose escalation are urgently needed.